1. At a Glance

Amrutanjan Health Care Ltd (AHCL), the 132-year-old balm king, is trading at ₹725 with a market cap of ₹2,097 Cr. The stock runs on caffeine and nostalgia—every Indian has either smelled their yellow-green balm or avoided their Electro+ drink in a cricket stadium. Sales for FY25 were ₹462 Cr with PAT at ₹55 Cr. P/E = 38.4 (industry ~33), OPM ~13.6%, and ROE at 16.5%. Zero meaningful debt (₹2 Cr only), but promoters trimmed their holding from ~50% to 46.5% in the past two years. In short: this company is older than Indian railways jokes, but still trying to reinvent itself with sanitary napkins and dental gels.

2. Introduction

Imagine a company born in 1893, when Victoria Terminus still ran steam engines. While India fought for freedom, Amrutanjan fought headaches. While Bollywood invented 1000 ways to show a sad song, Amrutanjan invented 1000 ways to apply balm. And here we are in 2025—same balm, same smell, new packaging, and a desperate attempt to grow beyond head pain.

Their portfolio is now a cocktail of three worlds:

• Pain balms and roll-ons (grandfather’s favorite).
• Women’s hygiene products under Comfy (mom’s go-to).
• Beverages like Electro+ energy drink (Gen Z influencer bait).

It’s a weird buffet: you can cure your migraine, manage your period, and gulp an isotonic drink in one basket. Diversification or identity crisis? You decide.

Question for you: Do you think companies this old should stick to their legacy (balm dominance), or experiment with beverages and sanitary napkins?

3. Business Model – WTF Do They Even Do?

Amrutanjan runs three divisions:

1. OTC Products (90% of revenue):
   • Head Category: Balms, roll-ons (73% market share in roll-ons).
   • Body Category: Pain patches, roll-ons.
   • Congestion: Cold/cough inhalers, herbal drinks.
     Basically, if you sneeze, ache, or cry, Amrutanjan has a small yellow-green tub waiting.
2. Women’s Hygiene (Comfy brand, ~28% of OTC revenue):
   Competes with giants like Whisper & Stayfree but plays the affordability card in Tier 2/3 towns.
3. Beverages (10% of revenue, 83% from Electro+):
   Sports drink that sponsors golf tournaments (a game 99% of Indians don’t watch) and cricketers like Ruturaj Gaikwad (a game 100% of Indians do).

Bonus: They entered oral care in FY24 with Stop Pain Dental Gel. Because why stop at head pain when you can claim gums too?

4. Financials Overview

Commentary: YoY profits doubled—someone’s balm worked. But QoQ looks like a hangover—sales dropped 30% as if Q4 stocked up for IPL and Q1 was spent sleeping.

5. Valuation Discussion – Fair Value Range

• P/E Method: EPS (TTM ~₹18.9). Industry avg P/E ~33.
  • Fair Range (30–35x): ₹567 – ₹662.
• EV/EBITDA Method: EV ~₹2,016 Cr, EBITDA ~₹81 Cr (TTM). EV/EBITDA = ~25x. Peers trade ~20–22x.
  • Fair Range: ₹1,620 – ₹1,780 Cr → ₹585 – ₹643 per share.
• DCF (assume 10% CAGR till FY28, discount 12%, terminal 4%): ₹600 – ₹700.

👉 Fair Value Range: ₹570 – ₹700.
(For educational purposes only, not investment advice.)

6. What’s Cooking – News, Triggers, Drama

• Capex Splash: Approved ₹123 Cr for a new sanitary napkin plant (1,200 pads per minute capacity). So from